Drug Approval | November 22, 2021
European Commission approves Roche’s Gavreto
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Achondroplasia is a genetic condition that causes severely short stature and disproportionate growth
The vaccine will be manufactured and marketed in the Philippines by SII under the brand name Covovax
The system is a compact new addition to the Roche Molecular portfolio, providing efficiency, simplicity and timely results to laboratories of all sizes.
Launching in 2022, its availability will be expanded to the global market
The European Commission (EC) granted marketing authorisation for Celltrion’s regdanvimab following a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) last week
Data demonstrates Ronapreve reduced risk of hospitalisation in certain patients and reduced risk of symptomatic Covid-19 infections in people exposed to the virus
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
Subscribe To Our Newsletter & Stay Updated
